Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials.

Details

Serval ID
serval:BIB_056EBDD62664
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials.
Journal
Journal of Clinical Oncology
Author(s)
Joosse A., Collette S., Suciu S., Nijsten T., Lejeune F., Kleeberg U.R., Coebergh J.W., Eggermont A.M., de Vries E.
ISSN
1527-7755 (Electronic)
ISSN-L
0732-183X
Publication state
Published
Issued date
2012
Volume
30
Number
18
Pages
2240-2247
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Abstract
PURPOSE: Several studies observed a female advantage in the prognosis of cutaneous melanoma, for which behavioral factors or an underlying biologic mechanism might be responsible. Using complete and reliable follow-up data from four phase III trials of the European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group, we explored the female advantage across multiple end points and in relation to other important prognostic indicators.
PATIENTS AND METHODS: Patients diagnosed with localized melanoma were included in EORTC adjuvant treatment trials 18832, 18871, 18952, and 18961 and randomly assigned during the period of 1984 to 2005. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% CIs for women compared with men, adjusted for age, Breslow thickness, body site, ulceration, performed lymph node dissection, and treatment.
RESULTS: A total of 2,672 patients with stage I/II melanoma were included. Women had a highly consistent and independent advantage in overall survival (adjusted HR, 0.70; 95% CI, 0.59 to 0.83), disease-specific survival (adjusted HR, 0.74; 95% CI, 0.62 to 0.88), time to lymph node metastasis (adjusted HR, 0.70; 95% CI, 0.51 to 0.96), and time to distant metastasis (adjusted HR, 0.69; 95% CI, 0.59 to 0.81). Subgroup analysis showed that the female advantage was consistent across all prognostic subgroups (with the possible exception of head and neck melanomas) and in pre- and postmenopausal age groups.
CONCLUSION: Women have a consistent and independent relative advantage in all aspects of the progression of localized melanoma of approximately 30%, most likely caused by an underlying biologic sex difference.
Keywords
Adolescent, Adult, Aged, Aged, 80 and over, Disease Progression, Disease-Free Survival, Female, Humans, Lymphatic Metastasis, Male, Melanoma/mortality, Melanoma/pathology, Middle Aged, Prognosis, Sex Characteristics, Skin Neoplasms/mortality, Skin Neoplasms/pathology, Treatment Outcome, Young Adult
Pubmed
Web of science
Create date
22/07/2012 21:05
Last modification date
20/08/2019 12:27
Usage data